Compared, cited
BPC-157 vs TB-500
The two most-stacked recovery peptides. BPC-157 has been studied more for local repair, TB-500 (a Thymosin Beta-4 fragment) more for systemic repair. Here is what the evidence actually shows for each - and why people run them together.
Last updated August 2026
Pepteca is a cited peptide reference. We do not sell peptides and take no affiliate money. Every figure below traces to a source on the linked library pages, with a clear line between what is clinically studied and what is community-reported.
| At a glance | BPC-157 | TB-500 |
|---|---|---|
| What it is | 15-amino-acid gastric peptide | 7-amino-acid Thymosin Beta-4 fragment |
| Half-life | Under 30 min (animal data) | Not established for the fragment |
| Human trials | None completed (a 2015 Phase I was cancelled) | Only on the full Tb4 molecule, not the fragment |
| Typical community dose | 250-500 mcg daily | 2-2.5 mg, 1-2x per week |
| Evidence base | Extensive animal data, thin human | Animal (mostly full Tb4), thin human |
| Regulatory status | WADA banned; FDA compounding caution | WADA banned; FDA bulk-substance concern |
How they differ
BPC-157 is a stable fragment of a protein found in stomach juice. In animal studies it supports localized repair - tendon, ligament, gut lining - and is thought to work through VEGF and nitric-oxide signaling. TB-500 is a lab-made snippet of Thymosin Beta-4 that binds actin, the internal scaffolding of cells, and is described as helping cells migrate to injury sites more systemically. The honest catch that separates them from the marketing: BPC-157's human evidence is a single cancelled Phase I trial, and TB-500's human trials were all run on the full Thymosin Beta-4 molecule (an IV safety study and dry-eye drops), not the injected fragment people actually buy.
Evidence and safety
Neither is approved by the FDA for any use, both are banned by the World Anti-Doping Agency, and every human injection protocol for both is community-derived, not clinically established. BPC-157 has the larger animal-study base behind it. For both, the practical risk is often the unregulated product itself - purity, mislabeling, and concentration - rather than the molecule.
Who fits which
Why people reach for BPC-157
Localized recovery goals - a specific tendon, joint, or gut issue - and daily dosing. It is the more animal-studied of the two.
Why people reach for TB-500
Broader, whole-body recovery goals and a less frequent (once or twice weekly) schedule, on the community rationale that it acts more systemically.
Why they are usually stacked, not chosen
The community 'Wolverine Stack' runs both together, pairing BPC-157's local action with TB-500's systemic one. No clinical trial has tested the combination - it is a community protocol.
The cited card
BPC-157
healing peptide
The cited card
TB-500
repair peptide
Questions people ask
Is BPC-157 or TB-500 better for healing?
Neither is proven for healing in humans - the controlled evidence is animal-based, and TB-500's human trials used the full Thymosin Beta-4 molecule rather than the injected fragment. People pick them for different rationales (BPC-157 more local, TB-500 more systemic) and often use them together. This is not medical advice.
Can you take BPC-157 and TB-500 together?
The community 'Wolverine Stack' does exactly that, on the theory that their mechanisms complement each other. No clinical trial has tested the combination, so treat it as community practice, not an established protocol.
Which one has more research behind it?
BPC-157 has the larger body of animal studies. TB-500's most relevant human data is actually on the parent molecule, Thymosin Beta-4, not the TB-500 fragment.
Related comparisons